bioAffinity Technologies

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage lung cancer and other diseases of the lung. The Companys first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is especially useful for patients whose lung cancer screening or other scan reveals a pulmonary nodule. Our first product, CyPath Flow Cytometry for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. CyPath Lung has the potential to dramatically increase overall...

Bioaffinity technologies operates in the Biotechnology industry.

Bioaffinity technologies's revenue is 1m - 10m

Bioaffinity technologies has 11 - 50 employees.